Vedolizumab for inflammatory bowel disease: Changing the game, or more of the same? By Tim Raine, United European Gastroenterology Journal October 2014 2: 333–344, DOI: 10.1177/2050640614550672.
In the above paper Figure 1 was labelled incorrectly. In the figure, the integrin target of vedolizumab appeared as α4β1 when this should have been α4β7, as correctly referred to in the figure legend and throughout the text. We apologise to readers for the error. The correct version of the figure is below: